Prostacyclin induction by high-density lipoprotein (HDL) in vascular smooth muscle cells depends on sphingosine 1-phosphate receptors: Effect of simvastatin

Thrombosis and Haemostasis

Volumn 100, Issue 1, 2008, Pages 119-126

  González Díez, María ^a   Rodríguez, Cristina ^a   Badimon, Lina ^a   Martínez González, José ^a  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

Antiplatelet agents; Atherothrombosis; Gene expression; Lipoproteins; Smooth muscle cells

Indexed keywords

CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYCLOOXYGENASE 2; ENZYME INHIBITOR; HIGH DENSITY LIPOPROTEIN; JTE 013; PROSTACYCLIN; SIMVASTATIN; SPHINGOSINE 1 PHOSPHATE RECEPTOR; SURAMIN; VPC 23019;

ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DESENSITIZATION; DOSE RESPONSE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SMOOTH MUSCLE FIBER; UPREGULATION; VASCULAR SMOOTH MUSCLE;

CELLS, CULTURED; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; CYCLOOXYGENASE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INDUCTION; EPOPROSTENOL; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPOPROTEINS, HDL; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PYRAZOLES; PYRIDINES; RECEPTORS, LYSOSPHINGOLIPID; RNA INTERFERENCE; RNA, MESSENGER; RNA, SMALL INTERFERING; SIMVASTATIN; SPHINGOSINE; SURAMIN; TIME FACTORS; UP-REGULATION;

EID: 46749085021     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH07-11-0675     Document Type: Article

References (42)

1. Assmann G, Nofer JR. Atheroprotective effects of high-density lipoproteins. Annu Rev Med 2003; 54: 321-341.
2. Badimon JJ, Badimon L, Galvez A, et al. HDL plasma fractions inhibit aortic fatty streaks in cholesterolfed rabbits. Lab Invest 1989; 60: 455-461.
3. Badimon JJ, Badimon L, Fuster V. Regression of atherosclerotic lesions by HDL plasma fraction in the cholesterol-fed rabbit. J Clin Invest 1990; 85: 1234-1241.
4. Mineo C, Deguchi H, Griffin JH, et al. Endothelial and antithrombotic actions of HDL. Circ Res 2006; 98:1352-1364.
5. Viñals M, Martínez-González J, Badimon L. HDL-Induced Prostacyclin release in smooth muscle cells is dependent on cyclooxygenase-2 (Cox-2). Arterioscler Thromb Vasc Biol 1997; 17: 3481-3488.
6. Vinals M, Martinez-Gonzalez J, Badimon L. Regulatory effects of HDL on smooth muscle cell prostacyclin release. Arterioscler Thromb Vasc Biol 1999; 19: 2405-2411.
7. Grosser T, Fries S, FitzGerald GA. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest 2006; 116: 4-15.
8. Martinez-Gonzalez J, Badimon L. Mechanisms underlying the cardiovascular effects of Cox-inhibition: benefits and risks. Curr Pharm Des 2007; 13: 2215-2227.
9. Schrör K, Weber AA. COX-2 inhibitors and the thrombotic risk. Thromb Haemost 2006; 96: 391-392.
10. 2 release and Cox-2 expression by VSMC. Eur J Clin Invest 2003; 33: 779-786.
11. 2 release induced by HDL in human VSMC: effect on Cox-2 up-regulation and MAPK signaling pathways activated by HDL. Atherosclerosis 2004; 174: 305-313.
12. Cockerill GW, Saklatvala J, Ridley SH, et al. HDL differentially modulate cytokine-induced expression of E-selectin and cyclooxygenase-2. Arterioscler Thromb Vasc Biol 1999; 19: 910-917.
13. Kimura T, Sato K, Kuwabara A, et al. Sphingosine 1-phosphate may be a major component of plasma lipoproteins responsible for the cytoprotective actions in human umbilical vein endothelial cells. J Biol Chem 2001; 276: 31780-31785.
14. Sachinidis A, Kettenhofen R, Seewald S, et al. Evidence that lipoproteins are carriers of bioactive factors. Arterioscler Thromb Vasc Biol 1999; 19: 2412-2421.
15. Waeber C, Blondeau N, Salomone S. Vascular sphingosine-1-phosphate S1P1 and S1P3 receptors. Drug News Perspect 2004; 17: 365-382.
16. Spiegel S. Sphingosine 1-phosphate: a ligand for the EDG-1 family of G-protein-coupled receptors. Ann NY Acad Sci 2000; 905: 54-60.
17. Nofer JR, Levkau B, Wolinska I, et al. Suppression of endothelial cell apoptosis by HDL and HDL-associated lysosphingolipids. J Biol Chem 2001; 276: 34480-34485.
18. Kimura T, Sato K, Malchinkhuu E, et al. HDL stimulates endothelial cell migration and survival through sphingosine 1-phosphate and its receptors. Arterioscler Thromb Vasc Biol 2003; 23: 1283-1288.
19. Nofer JR, van der Giet M, Tolle M, et al. HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. J Clin Invest 2004; 113: 569-581.
20. Nofer JR, Junker R, Pulawski E, et al. High density lipoproteins induce cell cycle entry in vascular smooth muscle cells via mitogen activated protein kinase-dependent pathway. Thromb Haemost 2001; 85: 730-735.
21. von Otte S, Paletta JR, Becker S, et al. Follicular fluid HDL-associated sphingosine 1-phosphate is a novel mediator of ovarian angiogenesis. J Biol Chem 2006; 281: 5398-5405.
22. Martínez-González J, Viñals M, Vidal F, et al. Mevalonate deprivation impairs IGF-I/insulin signaling in human VSMC. Atherosclerosis 1997; 135: 213-223.
23. Tamama K, Tomura H, Sato K, et al. HDL inhibits migration of VSMC through its sphingosine 1-phosphate component. Atherosclerosis 2005; 178: 19-23.
24. Martorell L, Martínez-González J, Crespo J, et al. Neuron-derived orphan receptor-1 (NOR-1) is induced by thrombin and mediates vascular endothelial growth. J Thromb Haemost 2007; 5: 1766-1773.
25. Murata N, Sato K, Kon J, et al. Interaction of sphingosine 1-phosphate with plasma components, including lipoproteins, regulates the lipid receptor-mediated actions. Biochem J 2000; 352: 809-815.
26. Malchinkhuu E, Sato K, Muraki T, et al. Assessment of the role of sphingosine 1-phosphate and its receptors in HDL-induced stimulation of astroglial cell function. Biochem J 2003; 370: 817-827.
27. Van Brocklyn JR, Lee MJ, Menzeleev R, et al. Dual actions of sphingosine-1-phosphate: extracellular through the Gi-coupled receptor Edg-1 and intracellular to regulate proliferation and survival. J Cell Biol 1998; 142: 229-240.
28. Ancellin N, Hla T. Differential pharmacological properties and signal transduction of the sphingosine 1-phosphate receptors EDG-1, EDG-3, and EDG-5. J Biol Chem 1999; 274: 18997-19002.
29. Damirin A, Tomura H, Komachi M, et al. Sphingosine 1-phosphate receptors mediate the lipid-induced cAMP accumulation through cyclooxygenase-2/ prostaglandin I2 pathway in human coronary artery smooth muscle cells. Mol Pharmacol 2005; 67: 1177-1185.
30. Tamama K, Kon J, Sato K, et al. Extracellular mechanism through the Edg family of receptors might be responsible for sphingosine-1-phosphate-induced regulation of DNA synthesis and migration of rat aortic smooth-muscle cells. Biochem J 2001; 353: 139-146.
31. Davis MD, Clemens JJ, Macdonald TL, et al. Sphingosine 1-phosphate analogs as receptor antagonists. J Biol Chem 2005; 280: 9833-9841.
32. Norata GD, Callegari E, Inoue H, Catapano AL. HDL3 induces cyclooxygenase-2 expression and prostacyclin release in human endothelial cells via a p38 MAPK/CRE-dependent pathway. Arterioscler Thromb Vasc Biol 2004; 24: 871-877.
33. Martínez-González J, Rodríguez-Rodríguez R, González-Díez M, et al. Oleanolic acid induces prostacyclin release in human vascular smooth muscle cells through a cyclooxygenase-2- dependent mechanism. J Nutr 2008; 138: 443-448.
34. Kim JI, Jo EJ, Lee HY, et al. Sphingosine 1-phosphate in amniotic fluid modulates cyclooxygenase-2 expression in human amnion-derived WISH cells. J Biol Chem 2003; 278: 31731-31736.
35. Nodai A, Machida T, Izumi S, et al. Sphingosine 1-phosphate induces cyclooxygenase-2 via Ca2+-dependent, but MAPK-independent mechanism in rat vascular smooth muscle cells. Life Sci. 2007; 80: 1768-1776.
36. Alfon J, Pueyo Palazon C, Royo T, Badimon L. Effects of statins in thrombosis and aortic lesion development in a dyslipemic rabbit model. Thromb Haemost. 1999; 81: 822-827.
37. Casani L, Sanchez-Gomez S, Vilahur G, Badimon L. Pravastatin reduces thrombogenicity by mechanisms beyond plasma cholesterol lowering. Thromb Haemost. 2005; 94: 1035-1041.
38. Martínez-González J, Badimon L. Influence of statin use on endothelial function: from bench to clinics. Curr Pharm Des 2007; 13: 1771-1786.
39. Igarashi J, Miyoshi M, Hashimoto T, et al. Statins induce S1P1 receptors and enhance endothelial nitric oxide production in response to high-density lipoproteins. Br J Pharmacol 2007; 150: 470-479.
40. Argraves KM, Argraves WS. HDL serves as an S1P signaling platform mediating a multitude of cardiovascular effects. J Lipid Res 2007; 48: 2325-2333.
41. Keul P, Tölle M, Lucke S, et al. The sphingosine-1-phosphate analogue FTY720 reduces atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2007; 27: 607-613.
42. Nofer JR, Bot M, Brodde M, et al. FTY720, a synthetic sphingosine 1 phosphate analogue, inhibits development of atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation 2007; 115: 501-508.